Search

everythinglearnresearchcommunity

for

Search:↓

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.

Sandalore®, a synthetic scent, improved hair loss and satisfaction in women with telogen effluvium.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Stromal Vascular Fraction might help with male sexual dysfunction, but more research is needed to confirm its safety and effectiveness.

Baricitinib is effective and safe for treating severe alopecia areata.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

PLD is an effective and safer alternative for treating breast cancer.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

High potency topical steroids are the most effective treatment for pediatric alopecia areata.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

PEGylated liposomal doxorubicin improves cancer treatment effectiveness and reduces side effects like heart damage and hair loss.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Bimatoprost is promising for treating some types of hair loss but needs more testing for androgenetic alopecia.

Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.